Proton Magnetic Resonance Spectroscopy with a Body Coil in the Diagnosis of Carcinoma Prostate

Overview

Journal Urol Res

Specialty Urology

Date 2003 Oct 10

PMID 14534764

Citations 4

Authors

Rajeev Kumar

Mahesh Kumar

N R Jagannathan

Narmada P Gupta

Ashok K Hemal

Affiliations

Soon will be listed here.

Abstract

We evaluate the feasibility of proton magnetic resonance spectroscopy ((1)H MRS) using a spine coil receiver (body coil) in the diagnosis of carcinoma prostate. Seventeen patients with biopsy-proven prostate carcinoma, five patients of benign prostatic hyperplasia (BPH) and five healthy young volunteers underwent (1)H MRS investigation. MRS was performed at 1.5 Tesla using a spine receiver coil for signal reception. In vivo citrate levels are reported as a ratio of citrate peak area to the sum of the areas of choline and creatine peak. MRS spectrum with good sensitivity and signal to noise (S/N) ratio was obtained in all 27 subjects. The citrate to creatine plus choline ratio was 0.31+/-0.25 in patients with cancer, 1.43+/-0.58 in BPH and 2.16+/-0.56 in controls. The difference in ratios between cancer and BPH and cancer and control was statistically significant ( p<0.01). Within the cancer group, there was a statistically significant decline in levels with higher-grade malignancy ( p<0.05). There were no complications of the procedure. There is a statistically significant decline in the ratio of citrate to choline plus creatine in the regions of cancer prostate when compared with BPH or normal control. The study demonstrates that MRS data can be reliably acquired using a spine coil receiver. MRS may also play a role in differentiating well-differentiated tumors from the anaplastic variety.

Citing Articles

MR Spectroscopic Imaging of Peripheral Zone in Prostate Cancer Using a 3T MRI Scanner: Endorectal versus External Phased Array Coils.

Nagarajan R, Margolis D, Raman S, Ouellette D, Sarma M, Reiter R Magn Reson Insights. 2014; 6:51-8.

PMID: 25114544 PMC: 4089813. DOI: 10.4137/MRI.S10861.

The role of metabolic imaging in radiation therapy of prostate cancer.

Zhang V, Westphalen A, Delos Santos L, Tabatabai Z, Shinohara K, Vigneron D NMR Biomed. 2013; 27(1):100-11.

PMID: 23940096 PMC: 3864570. DOI: 10.1002/nbm.3007.

Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage - impact of tissue environment.

Keshari K, Tsachres H, Iman R, Delos Santos L, Tabatabai Z, Shinohara K NMR Biomed. 2011; 24(6):691-9.

PMID: 21793074 PMC: 3653775. DOI: 10.1002/nbm.1738.

Role of magnetic resonance methods in the evaluation of prostate cancer: an Indian perspective.

Jagannathan N, Kumar V, Kumar R, Thulkar S MAGMA. 2008; 21(6):393-407.

PMID: 18633658 DOI: 10.1007/s10334-008-0122-6.

References

Schick F, Bongers H, Kurz S, Jung W, Pfeffer M, Lutz O . Localized proton MR spectroscopy of citrate in vitro and of the human prostate in vivo at 1.5 T. Magn Reson Med. 1993; 29(1):38-43. DOI: 10.1002/mrm.1910290109. View

Costello L, Franklin R . Concepts of citrate production and secretion by prostate. 1. Metabolic relationships. Prostate. 1991; 18(1):25-46. DOI: 10.1002/pros.2990180104. View

Lowry M, Liney G, Turnbull L, Manton D, Blackband S, Horsman A . Quantification of citrate concentration in the prostate by proton magnetic resonance spectroscopy: zonal and age-related differences. Magn Reson Med. 1996; 36(3):352-8. DOI: 10.1002/mrm.1910360305. View

Heerschap A, Jager G, van der Graaf M, Barentsz J, de la Rosette J, Oosterhof G . In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue. Anticancer Res. 1997; 17(3A):1455-60. View

Kurhanewicz J, Dahiya R, MacDonald J, Chang L, James T, Narayan P . Citrate alterations in primary and metastatic human prostatic adenocarcinomas: 1H magnetic resonance spectroscopy and biochemical study. Magn Reson Med. 1993; 29(2):149-57. DOI: 10.1002/mrm.1910290202. View

SCHNALL M, Imai Y, Tomaszewski J, POLLACK H, Lenkinski R, Kressel H . Prostate cancer: local staging with endorectal surface coil MR imaging. Radiology. 1991; 178(3):797-802. DOI: 10.1148/radiology.178.3.1994421. View

DiBiase S, Hosseinzadeh K, Gullapalli R, Jacobs S, Naslund M, Sklar G . Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2002; 52(2):429-38. DOI: 10.1016/s0360-3016(01)02609-8. View

Wefer A, Hricak H, Vigneron D, Coakley F, Lu Y, Wefer J . Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol. 2000; 164(2):400-4. View

Costello L, Franklin R . Concepts of citrate production and secretion by prostate: 2. Hormonal relationships in normal and neoplastic prostate. Prostate. 1991; 19(3):181-205. DOI: 10.1002/pros.2990190302. View

10.

Costello L, Franklin R . Aconitase activity, citrate oxidation, and zinc inhibition in rat ventral prostate. Enzyme. 1981; 26(6):281-7. DOI: 10.1159/000459195. View

11.

Kurhanewicz J, Vigneron D, Hricak H, Narayan P, Carroll P, Nelson S . Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology. 1996; 198(3):795-805. DOI: 10.1148/radiology.198.3.8628874. View

12.

Yu K, Hricak H . Imaging prostate cancer. Radiol Clin North Am. 2000; 38(1):59-85, viii. DOI: 10.1016/s0033-8389(05)70150-0. View

13.

Halliday K, Sillerud L . Differentiation of human tumors from nonmalignant tissue by natural-abundance 13C NMR spectroscopy. Magn Reson Med. 1988; 7(4):384-411. DOI: 10.1002/mrm.1910070403. View

14.

Scheidler J, Hricak H, Vigneron D, Yu K, Sokolov D, Huang L . Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study. Radiology. 1999; 213(2):473-80. DOI: 10.1148/radiology.213.2.r99nv23473. View

15.

Kaji Y, Wada A, Imaoka I, Matsuo M, Terachi T, Kobashi Y . Proton two-dimensional chemical shift imaging for evaluation of prostate cancer: external surface coil vs. endorectal surface coil. J Magn Reson Imaging. 2002; 16(6):697-706. DOI: 10.1002/jmri.10204. View

16.

Kurhanewicz J, Vigneron D, Males R, Swanson M, Yu K, Hricak H . The prostate: MR imaging and spectroscopy. Present and future. Radiol Clin North Am. 2000; 38(1):115-38, viii-ix. DOI: 10.1016/s0033-8389(05)70152-4. View

17.

Kurhanewicz J, Thomas A, Jajodia P, Weiner M, James T, Vigneron D . 31P spectroscopy of the human prostate gland in vivo using a transrectal probe. Magn Reson Med. 1991; 22(2):404-13. DOI: 10.1002/mrm.1910220248. View

18.

Kurhanewicz J, Vigneron D, Nelson S, Hricak H, MacDonald J, Konety B . Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology. 1995; 45(3):459-66. DOI: 10.1016/S0090-4295(99)80016-8. View